Brain Diseases on 7.0T Magnetic Resonance Imaging
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Magnetic resonance imaging.
- Who it may be relevant to
- Registry conditions: Brain Tumor, MRI, Cerebrovascular Disease. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.
Detailed description
7T MRI increased detection sensitivity, attain superior anatomic resolution, higher spatial and spectral specificity of advanced quantitative techniques, and shorter scan times than 3T MRI. When applied clinically, these benefits translate to increased detection sensitivity, and ultimately improved diagnostic and therapies confidence to inform decision making. This study aim to detect the image characteristics and diagnostic accuracy of brain diseases on 7T MRI.
Interventions
- Diagnostic test Magnetic resonance imaging
Patients recruited will receive Magnetic resonance imaging.
Primary outcome measures
- the correspondence between brain tumor cells found in the biopsies and region of interest(ROI) signal intension on the 7T MRI scan and 3T MRI scan [Time frame: within a month after biopsy]
- The visibility of white matter tracts on 7T MRI [Time frame: within a month after biopsy]
Secondary outcome measures (2)
- The correlation between the ROI's signal intension on 7T MRI scan and the KPS in 1 month after operation [Time frame: within a month after biopsy]
- The visibility of white matter tracts on 7T MRI and 3T MRI [Time frame: Six months after the biopsy]
Eligibility criteria
Inclusion criteria
- Age≥18 and ≤80
- Having brain diseases (eg: brain tumor, cerebrovascular diseases)
- Having no contraindications against MRI or intravenous contrast agent administration
- Clinically stable
Exclusion criteria
- Age<18 or >80
- Pregnancy and other contraindication to MRI scan
- Informed consent not obtained
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- Chinese PLA General Hospital — Beijing
Publications
- Duan Q, Lyu J, Liu Z, Hao F, Li R, Liu S, Hao X, Li J, Bian X, Duan C, Wang S, Wang W, Wang R, Duan L, Lou X. Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI. Neurology. 2025 Jun 10;104(11):e213617. doi: 10.1212/WNL.0000000000213617. Epub 2025 May 21. PMID 40397837
- Duan C, Bian X, Cheng K, Lyu J, Xiong Y, Xiao S, Wang X, Duan Q, Li C, Huang J, Hu J, Wang ZJ, Zhou X, Lou X. Synthesized 7T MPRAGE From 3T MPRAGE Using Generative Adversarial Network and Validation in Clinical Brain Imaging: A Feasibility Study. J Magn Reson Imaging. 2024 May;59(5):1620-1629. doi: 10.1002/jmri.28944. Epub 2023 Aug 9. PMID 37559435
Identifiers
NCT: NCT05287750 · Brain Diseases-ChinaPLAGH